Cashu
Arch Biopartners Inc. Advances Phase II Trial of LSALT Peptide for Kidney Injury Prevention
9 months ago
Stocks
Health Care
arch.v
Arch Biopartners Inc
TSXV: ARCH.V
+0.14 (+13.86%)
1.15
USD
At close at Feb 04, 15:30 UTC
Overview
Loading chart...
Key Stats
Market Cap
110.90M
Dividend Yield
0.00%
P/E Ratio
NaN
EPS
-0.04
Revenue
-84.70K
Avg. Volume
88.58K
About
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.